Usual doses of tramadol may cause visual and auditory hallucinationsHealth Canada safety review identifies new risk, particularly in people older than age 65. Combogesic, first acetaminophen–ibuprofen fixed-dose combox, now available Nonprescription product approved for short-term management of mild/moderate acute pain and for reduction of fever, in adults. Methadone as a pain treatment Managing people with opioid-use disorder in the emergency department Canadian Association of Emergency Physicians offers recommendations for emergency healthcare providers to help address Canada’s opioid crisis. U.S. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later U.S. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later NSAIDs may cause rare kidney problems in unborn babies and/or low levels of amniotic fluid. 5 Tips: Managing lower back pain Guidelines recommend pharmacists provide take-home naloxone to all opioid users Take-home naloxone kits are publicly funded in all Canadian provinces and territories and have been shown to effectively reduce opioid-related deaths. Emgality (galcanezumab) now indicated to reduce cluster headache frequency CGRP binding antibody is first drug approved by Health Canada to help prevent episodic cluster headaches New Canadian consensus guidelines for pharmacist prescribing of naloxone All patients receiving an opioid should be provided with take-home naloxone and counselled by a pharmacist Be alert for potential drug interactions with medical and recreational cannabis Review provides a comprehensive list of drug-drug interactions, with particular focus on Rx drugs with a narrow therapeutic index First Previous 9 10 11 12 13 Next Last